Study wrapper · #532
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
Editor's note
This is a mechanistic analysis within a randomized, placebo-controlled trial (50 participants) examining how the hormone FGF21 changes when tesamorelin reduces liver fat in people with HIV. Researchers reported that baseline FGF21 was positively associated with liver fat, that FGF21 tended to decrease with tesamorelin versus placebo (a borderline, non-significant trend, p=0.06), and that reductions in FGF21 across the cohort correlated with reductions in liver fat and liver-injury markers. The authors interpret this as evidence that tesamorelin improves liver fat through pathways other than raising FGF21. As a small mechanistic study with a borderline primary comparison and biomarker endpoints, it is best read as hypothesis-refining context on how tesamorelin's liver benefit is (and is not) mediated.
Plain-language abstract
FGF21 is a hormone that is paradoxically high in people with fatty liver, possibly as a compensatory response. Researchers used a randomized, placebo-controlled trial in 50 people with HIV and extra belly fat to see how FGF21 changed as tesamorelin reduced liver fat. At the start, higher FGF21 went along with more liver fat. FGF21 tended to fall with tesamorelin compared with placebo, though this particular comparison was borderline and not statistically firm. Across everyone in the study, bigger drops in FGF21 matched bigger drops in liver fat and in markers of liver stress. The authors conclude that FGF21 rises when the liver is fatty and falls as that improves, but that tesamorelin likely helps the liver through routes other than changing FGF21. This small study examined a hormone marker rather than long-term liver health.